抗抑郁药导致体重增加的研究进展

doi:10.19803/j.1672-8629.2020.07.13

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (7): 444-447.
DOI: 10.19803/j.1672-8629.2020.07.13

抗抑郁药导致体重增加的研究进展

郑雪, 司继刚^*

淄博市中心医院临床药学科,山东淄博 255036

收稿日期:2020-02-25 修回日期:2020-06-22 出版日期:2020-07-15 发布日期:2020-06-22
通讯作者: ^*司继刚,男,硕士,主任药师,临床药学。E-mail：sjg1019@163.com
作者简介:郑雪,女,硕士,主管药师,心血管药物临床合理应用及医院药学管理。

Research Progress of Weight Gain Induced by Antidepressants

ZHENG Xue, SI Jigang

Department of Clinical Pharmacy, Central Hospital of Zibo, Zibo Shandong 255036, China

Received:2020-02-25 Revised:2020-06-22 Online:2020-07-15 Published:2020-06-22

摘要/Abstract

摘要： 目的比较不同抗抑郁药尤其是新型抗抑郁药对体重的影响程度,以寻找预防及处理措施。方法检索国内外发表的抗抑郁药导致增重增加的文章,总结对抗抑郁药引起体重增加的表现和原因。结果诸多抗抑郁药都可导致体重增加,在治疗的第1年和第2年体重增加最为明显。最重要的原因是阻断H₁受体和5-羟色胺2C受体后进食量增加。体重增加发生最多的是米氮平、选择性5-羟色胺再摄取抑制剂等,安非他酮、沃替西汀、维拉唑酮、米那普仑不增加体重。抗抑郁治疗过程中出现体重增加,可通过改变生活方式及更换药物进行解决。结论医生应用抗抑郁药应重视可能导致的体重增加,合理选择药物,对患者进行适当的告知和提醒,出现体重增加后及时进行干预,保证患者治疗的安全和有效。

关键词: 抗抑郁药, 体重增加, 原因, 处理措施

Abstract: Objective Antidepressants, especially new antidepressants, are widely used, and the weight gain caused by them has been taken seriously into account. Methods Search the articles about weight gain caused by antidepressants published at home and abroad, and summarize the manifestations and reason of weight gain caused by antidepressants, and compare the effects of different drugs on weight, and look for prevention and treatment measures. Results Alot of antidepressants can lead to weight gain, especially in the second and third year. The most important reason is the increase of intake after blocking H1 receptor and 5-HT2C receptor. Mirtazapine has been supposed to causes the most weight gain, then SSRI and so on. Bupropion, wotexitin, verazolone and minopram did not gain weight. During the course of antidepressant treatment, weight gain can be solved by changing life style and replacement of drugs. Conclusion Doctors should pay attention to the possible weight gain when using antidepressants。It is improment to choose drugs reasonably,to inform and remind patients appropriately, to intervene in time after weight gain.

Key words: antidepressants, weight gain, reason, treatment measures

中图分类号:

郑雪, 司继刚. 抗抑郁药导致体重增加的研究进展[J]. 中国药物警戒, 2020, 17(7): 444-447.

ZHENG Xue, SI Jigang. Research Progress of Weight Gain Induced by Antidepressants[J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 444-447.

参考文献

[1] 庄红艳,刘珊珊,果伟,等.121例老年精神科药品不良反应报告分析[J].中国药物警戒,2017,14(2):105-108.
[2] 李莹, 都丽萍, 李玲玲, 等. 药物对体重的影响[J]. 药物不良反应杂志, 2017, 19(2):121-125.
[3] Khalil E, Bruno F, Romain C, et al.Early weight gain predicts later weight gain in depressed patients treated with antidepre-ssants: findings from the METADAP cohort[J].Journal of Affective Disorders, 2018,214(1):22-28.
[4] Arterburn D, Sofer T, Boudreau D, et al.Long-Term Weight Change after Initiating Second-Generation Antidepressants[J].Journal of Clinical Medicine,2016,5(4):48-60.
[5] Shi Z, Atlantis E, Taylor AW, et al.SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles:results from a 4-year Australian follow-up study[J].BMJ Open,2017,7(8):e016224.
[6] Gafoor R, Booth HP, Gulliford MC.Antidepressant utilization and incidence of weight gain during 10 years' follow-up:population based cohort study[J].BMJ, 2018,23(361):k1951.
[7] Vandenberghe F, Gholamrezaee M, SaigíMorgui N, et al.Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment[J].Journal of Clinical Psychiatry, 2015, 76(11):e1417.
[8] Caleb C, Steven C, Rong Wan, et al.The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C[J].Journal of Clinical Investigation, 2017,127(9):3402-3406.
[9] Salvi V, Mencacci C, Barone-Adesi F.The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C[J]. European neuropsychopharmacology,2016, 26(10):1673-1677.
[10] Virginio S, Claudio M, Francesco BA.Antidepressant induced weight gain associated with anti-histaminergic activity[J]. BMJ, 2018,7(362):k3222
[11] Salvi V, Barone-Adesi F, D’Ambrosio V,et al. High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder[J].Psychopharmacology (Berl), 2016,233(1):49-56.
[12] Serretti A, Mandelli L.Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis[J]. The Journal of Clinical Psychiatry, 2010, 71(10):1259-1272.
[13] Blumenthal SR, Castro VM, Clements CC, et al.An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use[J].JAMA Psychiatry,2014, 71(8):889-896.
[14] Gafoor R, Booth HP, Gulliford MC.Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study[J]. BMJ,2018(361):k1951.
[15] Serretti A,Mandelli L.Antidepressants and body weight a comp-rehensive review and meta-anaylsis[J].J Clin Psychiatry,2010,71(10):1259-1272.
[16] Blumenthal SR, Castro VM, Clements CC, et al.An electronic health records study of long-term weight gain following antidep-ressant use[J]. JAMA Psychiatry,2014,71(8):889-896.
[17] Ravindran PP, Zang W, Renukunta S,et al.Effect of comedication of bupropion and other antidepressants on body mass index[J].Ther Adv Psychopharmacol,2015,5(3):158-165.
[18] Patten S B.Bupropion confirmed not to cause weight gain in a real-world clinical population[J].Evidence-based mental health,2015,18(2):57-58.
[19] lacobsen PL,Harper L.Chrones L,et al.Safety and tolerability of vortioxetine (15 and 20mg)in patients with major depnessive disonder esuls of an open-abel,fexible dose,52-week extension study[J]. Int Clin Psychopharmacol,2015,30(5):255-264.
[20] Boulenger LH, Olsen CK.Efficacy and safety of vortioxcetine(Lu AAa1004),15 and 20 mg/day:a randomized, double-blind,placebo-controlled,duloxetine-referenced studv in the acule treatment of adult patients with major depressive disornder[J].Int Clin Peycho pharmacol,2014,29(3):3138-3149.
[21] McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone[J].Neuropsychiatr Dis Treat,2017(13):2913-2919.
[22] Durgam S, Chen C, Migliore R, et al.Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebocontrolled study[J]. Depress Anxiety, 2019,36(3):225-234.
[23] Citrome L.Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?[J]. Int J Clin Pract,2014,68(1):60-82.
[24] Ageu LS, Levai CM, Andreescu NI, et al.Modern molecular study of weight gain related to antidepressant treatment: clinical implications of the pharmacogenetic testing[J].Romanian journal of morphology and embryology,2018, 59(1):165-173.
[25] Schwartz TL, Meszaros ZS,Khan R,et al. How to control weight gain when prescribing antidepressants[J].Current Psychiatry,2016,15(6):30-32,35-36,39-39,47-48.
[26] Jeffrey S,MacDaniels,Thomas L,et al. How to control weight gain when prescribing antidepressants: address diet and exercise first, then consider switching antidepressants or prescribing an adjunctive agent[J]. Current Psychiatry,2016,15(6):31-40.

抗抑郁药导致体重增加的研究进展

Research Progress of Weight Gain Induced by Antidepressants

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

[1]	陈瑛, 李亮, 吉文岳, 吴纯启, 董延生. 生物胺系统抗抑郁药物依赖性评价研究进展[J]. 中国药物警戒, 2022, 19(1): 113-116.
[2]	祁献芳,张龙,陈晓萌,孙俊. 我院住院患者用药错误分析[J]. 中国药物警戒, 2017, 14(12): 760-763.
[3]	陈宁,王婷,马莉. 345例用药错误原因分析及对策[J]. 中国药物警戒, 2015, 12(2): 106-109.
[4]	平静，王均宁，张成博. 细辛中毒及预防的研究分析[J]. 中国药物警戒, 2012, 9(6): 350-353.
[5]	张勇，任丽华，程跃. 我院门诊西药房患者退药原因分析[J]. 中国药物警戒, 2012, 9(3): 164-165.
[6]	陶庆梅，孙凤，郁凯，翟伟，詹思延. 骨科植入物不良事件发生原因及处置方式系统综述[J]. 中国药物警戒, 2012, 9(2): 104-109.
[7]	李宏. 对《药品不良反应信息通报》中通报两次的药品分析[J]. 中国药物警戒, 2011, 8(6): 343-345.
[8]	张英,崔向丽,杨萍,贾颖,刘静,潘华,赵志刚 . SSRI和SNRI类抗抑郁药的不良反应[J]. 中国药物警戒, 2010, 7(9): 554-555.
[9]	蒋冬贵, 王刚, 努尔江·沙布开, 李雷. 医疗器械不良事件发生原因与分析方法[J]. 中国药物警戒, 2010, 7(1): 7-11.